This is a Phase 2b study to evaluate the efficacy and safety of Imeroprubart in adults with CIDP.

This is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Imeroprubart in adult participants with active CIDP.

Inclusion Criteria:

• Have met clinical diagnostic criteria for typical CIDP or one of the following CIDP variants: multifocal CIDP or motor CIDP per the 2021 European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) Guideline on Diagnosis and Treatment of CIDP.
• Have electrodiagnostic test results supporting the diagnosis of CIDP per the EAN/PNS guideline on diagnosis and treatment of CIDP.
• Are currently on, and have been receiving chronic, stable doses of systemic corticosteroids (i.e., daily or every other day oral or pulse regimen), or immunoglobulin therapy (IVIg or SCIg) ± low dose oral corticosteroids for at least 3 months for the treatment of CIDP at the time of the Screening Visit.

Additional inclusion criteria are defined in the protocol.

Exclusion Criteria:

• Have current or prior history of IgM paraproteinemia with or without anti-myelin-associated-glycoprotein antibodies.

• Have distal, sensory, or focal CIDP, or have a diagnosis of autoimmune nodopathy per the EAN/PNS guideline on diagnosis and treatment of CIDP.

• Have polyneuropathy of causes other than CIDP including but not limited to:

  • Multifocal motor neuropathy
  • Hereditary demyelinating neuropathy
  • Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin change syndromes (i.e., POEMS)
  • Lumbosacral radiculoplexus neuropathy
  • Systemic illnesses including vitamin deficiency syndromes and paraneoplastic neuropathies
  • Drug- or toxin-induced

• Have diabetes mellitus (DM) and meets any of the following criteria:

  • Does not have both typical CIDP and strong evidence of demyelination on nerve conduction study.
  • In the opinion of the Investigator, there is evidence of poorly controlled DM preceding the diagnosis of CIDP.
  • In the opinion of the Investigator, there is evidence of poorly controlled DM at screening.

• Have a history of myelopathy or evidence of central demyelination. Additional exclusion criteria are defined in the protocol.

Sponsor, care provider and outcome assessor will also be blinded.